NASDAQ:RUBY

Rubius Therapeutics Stock Forecast, Price & News

$24.05
+0.22 (+0.92 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.31
Now: $24.05
$24.50
50-Day Range
$8.02
MA: $20.32
$32.01
52-Week Range
$4.20
Now: $24.05
$38.71
Volume573,871 shs
Average Volume1.71 million shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600
Employees204
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.44 per share

Profitability

Net Income$-163,460,000.00

Miscellaneous

Market Cap$1.95 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable

Headlines

Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Down to $22.61
April 14, 2021 |  americanbankingnews.com
Rubius Therapeutics (NASDAQ:RUBY) Shares Up 6.7%
April 13, 2021 |  americanbankingnews.com
Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Up to $26.50
April 1, 2021 |  americanbankingnews.com
Rubius Therapeutics (NASDAQ:RUBY) Shares Up 9.9%
March 31, 2021 |  americanbankingnews.com
Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Down to $31.78
March 26, 2021 |  americanbankingnews.com
Rubius Therapeutics (NASDAQ:RUBY) PT Raised to $20.00
March 22, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

329th out of 2,021 stocks

Biological Products, Except Diagnostic Industry

43rd out of 177 stocks

Analyst Opinion: 1.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
$24.05
+0.22 (+0.92 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

Is Rubius Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Rubius Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View analyst ratings for Rubius Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Rubius Therapeutics?

Wall Street analysts have given Rubius Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rubius Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Rubius Therapeutics?

Rubius Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 6,390,000 shares, a decrease of 32.7% from the March 15th total of 9,490,000 shares. Based on an average daily volume of 1,810,000 shares, the days-to-cover ratio is presently 3.5 days. Currently, 17.9% of the company's stock are short sold.
View Rubius Therapeutics' Short Interest
.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its earnings results on Tuesday, February, 23rd. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.03.
View Rubius Therapeutics' earnings history
.

How has Rubius Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RUBY shares have increased by 267.2% and is now trading at $24.05.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RUBY?

4 Wall Street analysts have issued 1 year price targets for Rubius Therapeutics' shares. Their forecasts range from $10.00 to $40.00. On average, they expect Rubius Therapeutics' share price to reach $23.33 in the next year. This suggests that the stock has a possible downside of 3.0%.
View analysts' price targets for Rubius Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 59, Pay $495k)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 58, Pay $785.88k)
  • Ms. Maiken Keson-Brookes, Chief Legal Officer & Corp. Sec. (Age 48, Pay $190.17k)
  • Mr. Jose Carmona, CFO, Principal Accounting Officer & Treasurer (Age 49)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 52)
  • Mr. Spencer Fisk, Sr. VP of Manufacturing & CTO
  • Mr. Laurence A. Turka M.D., Chief Scientific Officer (Age 62)
  • Ms. Lori Melancon, VP of Corp. Communications & Investor Relations
  • Ms. Elhan Webb C.F.A., VP of Investor Relations
  • Mr. Theo Proukou, Sr. VP & Chief People Officer

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics CEO Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among Rubius Therapeutics' employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $24.05.

How much money does Rubius Therapeutics make?

Rubius Therapeutics has a market capitalization of $1.95 billion. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

Rubius Therapeutics employs 204 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

Where are Rubius Therapeutics' headquarters?

Rubius Therapeutics is headquartered at 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.